Democratic Republic of the Congo; Penicillin prophylaxis; Sickle cell disease; challenges; current practices; hydroxyurea; immunization; malaria chemoprophylaxis; management
Abstract :
[en] BACKGROUND: The Democratic Republic of the Congo (DRC) is the third most affected country worldwide by sickle cell disease (SCD). However, this disease is still orphaned in the country; large-scale control actions are rare, and little is known about its management. OBJECTIVE: To assess current practices in the management of SCD in Kisangani, DRC. METHODS: This cross-sectional study was conducted in six health facilities in Kisangani. It involved 198 presumed sickle cell patients attending the above health facilities. The study focused on the sociodemographic and clinical data of the participants, obtained through a clinical examination and their medical records. Diagnostic confirmation of SCD was made by high-performance liquid chromatography coupled to mass spectrometry. Data were analyzed using SPSS 20.0. RESULTS: The diagnosis of SCD was confirmed in 194 (98.0%; 95% CI: 94.9-99.2) participants, while it was not confirmed in 4 (2.0%; 95% CI: 0.8-5.1) participants. The diagnosis was mainly made by the Emmel test (42.9%). 45.8% of participants had previously been transfused with the blood of their parents. Folic acid was taken by 48.5% of participants and the previous intake of hydroxyurea was reported in 5.1% of participants. The participants vaccinated against Pneumococcus were 13.6% and against Haemophilus influenzae type b 28.3%. Penicillin prophylaxis was received by only 1.5% and malaria prophylaxis by 11.6% of participants. CONCLUSION: Standard-care practices for SCD patients in Kisangani are insufficient. The Congolese government should regard this disease as a health priority and consider actions to improve its management.
Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013; 38 (9861): 142–151. DOI: 10.1016/S0140-6736(12)61229-X.
Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell anemia in Sub-Saharan Africa. N Engl J Med. 2019; 380 (2): 121–131. DOI: 10.1056/NEJMoa1813598.
Aygun B, Odame I., A global perspective on sickle cell disease. Pediatr Blood Cancer. 2012; 59 (2): 386–390. DOI: 10.1002/pbc.24175.
Mulumba LL, Wilson L., Sickle cell disease among children in Africa: An integrative literature review and global recommendations. Int J Afr Nurs Sci. 2015; 3: 56–64. DOI: 10.1016/J.IJANS.2015.08.002.
WHO, Africa Regional Committee. Sickle-cell anaemia: a strategy for the who African region. Report of the Sixtieth Session Malabo, Equatorial Guinea, 30 August–3 September 2010AFR/RC60/8 [cited 2020 May 17]. Available from: https://apps.who.int/iris/handle/10665/1682.
Wailoo K., Sickle cell disease–a history of Progress and Peril. N Engl J Med. 2017; 376 (9): 805–807. DOI: 10.1056/NEJMp1700101.
Rahimy MC, Gangbo A, Ahouignan G, et al. Newborn screening for sickle cell disease in the Republic of Benin. J Clin Pathol. 2009; 62 (1): 46–48. DOI: 10.1136/jcp.2008.059113.
De Montalembert M, Tshilolo L., Is therapeutic progress in the management of sickle cell disease applicable in sub-Saharan Africa? Med Trop. 2007; 67 (6): 612–616.
Allali S, Chalumeau M, Launay O, et al. Conjugate Haemophilus influenzae type b vaccines for sickle cell disease. Cochrane Database Syst Rev. 2018; 8 (8): CD011199. DOI: 10.1002/14651858.CD011199.
Tonen-Wolyec S, Batina-Agasa S, Muwonga J, et al. Acceptability, feasibility, and individual preferences of blood-based HIV self-testing in a population-based sample of adolescents in Kisangani, Democratic Republic of the Congo. PLoS One. 2019; 14 (7): e0218795. DOI: 10.1371/journal.pone.0218795.
Agasa B, Bosunga K, Opara A, et al. Prevalence of sickle cell disease in a northeastern region of the Democratic Republic of Congo: what impact on transfusion policy? Transfus Med. 2010; 20 (1): 62–65. DOI: 10.1111/j.1365-3148.2009.00943.x.
Boemer F, Cornet Y, Libioulle C, et al. 3-years experience review of neonatal screening for hemoglobin disorders using tandem mass spectrometry. Clin Chim Acta. 2011; 412 (15-16): 1476–1479. DOI: 10.1016/j.cca.2011.04.031.
Boemer F, Ketelslegers O, Minon JM, et al. Newborn screening for sickle cell disease using tandem mass spectrometry. Clin Chem. 2008; 54 (12): 2036–2041. DOI: 10.1373/clinchem.2008.106369.
Kasai E, Boemer F, Djang’eing’a R, et al. Systematic screening of neonatal sickle cell disease with HemoTypeSCTM Kit-test: case study and literature review. Open J Blood Dis. 2020; 10: 12–21. DOI: 10.4236/ojbd.2020.101002.
Segbena AY, Guindo A, Buono R, et al. Diagnostic accuracy in field conditions of the sickle SCAN® rapid test for sickle cell disease among children and adults in two West African settings: the DREPATEST study. BMC Hematol. 2018; 18: 26, DOI: 10.1186/s12878-018-0120-5.
Aloni MN, Nkee L., Challenge of managing sickle cell disease in a pediatric population living in Kinshasa, democratic Republic of Congo: a sickle cell center experience. Hemoglobin. 2014; 38 (3): 196–200. DOI: 10.3109/03630269.2014.896810.
Lowenthal EA, Mayo MS, Cornwell PE, et al. Homocysteine elevation in sickle cell disease. J Am Coll Nutr. 2000; 19 (5): 608–612. DOI: 10.1080/07315724.2000.10718958.
Liu YK., Folic acid deficiency in sickle cell anaemia. Scand J Haematol. 1975; 14 (1): 71–79. DOI: 10.1111/j.1600-0609.1975.tb00295.x.
Al-Yassin A, Osei A, Rees D., Folic acid supplementation in children with sickle cell disease. Arch Dis Child. 2012; 97: A91–A92. DOI: 10.1136/archdischild-2012-301885.219.
Ofakunrin AOD, Oguche S, Adekola K, et al. Effectiveness and safety of hydroxyurea in the treatment of sickle cell anaemia children in Jos, North Central Nigeria. J Trop Pediatr. 2020; 66 (3): 290–298. DOI: 10.1093/tropej/fmz070.
Thornburg CD, Files BA, Luo Z, et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood. 2012; 120 (22): 4304–4310. DOI: 10.1182/blood-2012-03-419879.
Brecher ME. American Association of Blood Banks. Technical manual. 14th ed., Bethesda (MA): Brecher ME; 2002.
Batina-Agasa S, Kambale-Kombi P, Kabamba P, et al. Sickle cell trait among blood donors in the Democratic Republic of the Congo: which transfusion policy for sickle cell patients? ISBT ScSer. 2020; 1–4. DOI: 10.1111/voxs.12580
Batina A, Kabemba S, Malengela R., Marqueurs infectieux chez les donneurs de sang en République Démocratique du Congo (RDC) [Infectious markers among blood donors in Democratic Republic of Congo (DRC)]. Rev Med Brux. 2007; 28 (3): 145–149.
Mukendi PC, Katala MK, Ndala DB, et al. Seroprevalence of Hepatitis B among blood donors in Mbuji-Mayi, “Case of Dipumba General Hospital” (DRC). Open Access Library Journal. 2017; 2017 (04): 1–7. DOI: 10.4236/oalib.1103503.
Treleaven J, Gennery A, Marsh J, et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol. 2011; 152 (1): 35–51. DOI: 10.1111/j.1365-2141.2010.08444.x.
CDC. 2018. Vaccine recommendations for patients with sickle cell disease (includes Hgb SS, Hgb SC, Hgb SB null and Hgb SB minor). [cited 2020 May 30]. Available from: https://missionhealth.org/wp-content/uploads/2018/04/CDC-Vaccine-Recommendations-for-Patients-with-Sickle-Cell-Disease.pdf.
Galadanci N, Wudil BJ, Balogun TM, et al. Current sickle cell disease management practices in Nigeria. Int Health. 2014; 6 (1): 23–28. DOI: 10.1093/inthealth/iht022.
Rankine-Mullings AE, Owusu-Ofori S., Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev. 2017; 10 (10). CD003427. DOI: 10.1002/14651858.CD003427.pub4.
Yee ME, Bakshi N, Graciaa SH, et al. Incidence of invasive Haemophilus influenzae infections in children with sickle cell disease. Pediatr Blood Cancer. 2019; 66 (6): e27642. DOI: 10.1002/pbc.27642.
Taylor SM, Messina JP, Hand CC, et al. Molecular malaria epidemiology: mapping and burden estimates for the Democratic Republic of the Congo, 2007. PLoS One. 2011; 6 (1): e16420. DOI: 10.1371/journal.pone.0016420.
Frimpong A, Thiam LG, Arko-Boham B, et al. Safety and effectiveness of antimalarial therapy in sickle cell disease: a systematic review and network meta-analysis. BMC Infect Dis. 2018; 18 (1): 650, Published 2018 Dec 12. DOI: 10.1186/s12879-018-3556-0.
